10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2026)

10x Genomics has reported Other Non-Current Liabilities for 9 years, with the latest figure at $6.4 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 18.9% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 18.9% YoY) and the FY2025 annual result came in at $6.5 million, changed N/A from the prior year.
• Other Non-Current Liabilities fell to $6.4 million in Q1 2026 per TXG's latest filing, from $6.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $10.1 million in Q3 2023 and troughed at $3.0 million in Q4 2022.
• A 5-year average of $6.3 million and a median of $6.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 63.88% in 2022, then surged 77.04% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $3.0 million in 2022, then jumped by 43.65% to $4.3 million in 2023, then gained by 15.67% to $4.9 million in 2024, then soared by 30.86% to $6.5 million in 2025, then fell by 0.82% to $6.4 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $6.4 million, $6.5 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.